Abstract

The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Keywords

MedicineBevacizumabCarboplatinLung cancerChemotherapyInternal medicinePaclitaxelHazard ratioOncologyClinical endpointSurgeryGastroenterologyRandomized controlled trialCisplatinConfidence interval

Affiliated Institutions

Related Publications

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

Philip Bonomi , KyungMann Kim , Diane L. Fairclough +5 more

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine...

2000 Journal of Clinical Oncology 593 citations

Publication Info

Year
2006
Type
article
Volume
355
Issue
24
Pages
2542-2550
Citations
5741
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5741
OpenAlex
265
Influential
4745
CrossRef

Cite This

Alan Sandler, Robert J. Gray, Michael C. Perry et al. (2006). Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. New England Journal of Medicine , 355 (24) , 2542-2550. https://doi.org/10.1056/nejmoa061884

Identifiers

DOI
10.1056/nejmoa061884
PMID
17167137

Data Quality

Data completeness: 81%